Selank: A Quieter Anxiety, A Sharper Attention

The short version

Selank is a synthetic heptapeptide — seven amino acids with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It extends the natural immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg, a fragment of the IgG heavy chain) with the same C-terminal Pro-Gly-Pro tail used in Semax, added to improve metabolic stability. Its anxiolytic activity in rodent studies is attributed primarily to two non-benzodiazepine mechanisms: positive allosteric modulation of GABA receptors ^[8] and inhibition of the enkephalin-degrading enzymes that normally break down the body's own calming peptides ^[7]. In rat frontal cortex, a single dose shifted expression of 45 GABA-pathway genes within one hour ^[10].

Selank is a distinctly different compound from Semax — different structure, different primary mechanism, different clinical application in Russian medicine (anxiolytic rather than cognitive/neuroprotective), and different community use pattern. The single shared feature is the C-terminal Pro-Gly-Pro stabilizing tail and some overlap in enkephalinase inhibition ^[7]. This page describes what was studied; it gives no advice on use and lists no human dose.

What it is

Selank is also known as TP-7 and as the heptapeptide Selank or tuftsin analogue Selank. Its defining structural feature is the combination of tuftsin's four-residue immune-signaling sequence with the Pro-Gly-Pro tripeptide that stabilizes it against serum peptidases. The tuftsin origin is important because it provides Selank with an immunomodulatory character that purely synthetic anxiolytics do not share — in clinical research, Selank has been observed to shift the Th1/Th2 cytokine balance in patients with anxiety disorders ^[12], a dimension that has no parallel in classical benzodiazepine pharmacology.

Selank is not an approved medicine in the US or EU. It holds regulatory registration as an anxiolytic prescription drug in Russia, where it has been studied in anxiety-asthenic disorders and related conditions. Elsewhere it is sold strictly as a research chemical.

How it works

Two main, non-benzodiazepine mechanisms characterize Selank's anxiolytic profile in the literature.

GABA-receptor modulation. A 2018 review established that Selank acts as a positive allosteric modulator of GABA-receptor binding: it increased [³H]GABA binding in a subtype-selective, concentration-dependent fashion, and — notably — it could block the modulatory activity of diazepam and olanzapine, indicating overlapping but distinct binding sites ^[8]. In rat frontal cortex, Selank administration changed the expression of 45 genes involved in GABAergic neurotransmission within one hour, and these expression shifts correlated positively with those produced by GABA itself, providing a gene-level confirmation of GABAergic involvement ^[10]. In a chronic mild stress model, co-administration of Selank with diazepam produced the largest anxiety reduction of any treatment condition ^[9].

Enkephalinase inhibition. Selank inhibits the serum enzymes that degrade enkephalins (neprilysin-type peptidases) with an IC50 of roughly 20 micromolar — comparable to, though slightly less potent than, Semax at about 10 micromolar in the same assay ^[7]. Stabilizing endogenous enkephalins prolongs their opioid-receptor signaling, providing a calming effect via a pathway entirely separate from GABA.

BDNF and neuroplasticity. Intranasal Selank increased BDNF expression in the rat hippocampus in vivo ^[11], linking the peptide to neuroplasticity-related signaling and providing a mechanistic rationale for the longer-term mood and cognitive effects some users describe.

Immunomodulation. As a tuftsin analog, Selank carries immunomodulatory activity independent of its anxiolytic profile: in patients with anxiety-asthenic disorders it shifted the Th1/Th2 cytokine balance and modulated IL-6 expression ^[12], characterizing it as a novel class of compound with both psychiatric and immune dimensions.

What the research shows

GABA-receptor pharmacology (2018). The review of Selank's molecular mechanisms established it as a positive allosteric modulator of [³H]GABA binding with subtype-selective, concentration-dependent action, capable of blocking the modulatory activity of established GABAergic drugs ^[8].

Gene expression in frontal cortex (2016). A single Selank dose changed expression of 45 GABA-related genes at 1 hour and 22 at 3 hours in rat frontal cortex; the direction of change positively correlated with GABA-induced expression changes, independently confirming the GABAergic mechanism at a genomic level ^[10].

Chronic mild stress model (2017). In rats subjected to unpredictable chronic mild stress, the combination of diazepam and Selank was the most effective at reducing anxiety and restoring behavior toward pre-stress levels — more effective than either drug alone — consistent with Selank having an additive GABAergic interaction ^[9].

BDNF in hippocampus (2008). Intranasal Selank regulated (increased) BDNF expression in rat hippocampus in vivo, providing a neuroplasticity-linked mechanism for its nootropic effects beyond simple anxiety suppression ^[11].

Immunomodulation in human patients (2008). In patients with anxiety-asthenic disorders, Selank altered the Th1/Th2 cytokine balance and modulated IL-6 expression; the authors concluded Selank acts as a novel immunomodulator alongside its anxiolytic action ^[12].

Human context. Human evidence for Selank is limited to a small set of Russian clinical studies over two- to four-week courses, largely in Russian-language journals. No large randomized controlled trials have been published in Western literature, and pharmacokinetics of intact Selank in humans are not well characterized in mainstream databases.

Reported effects, cautions & safety

The following community-reported effects are anecdotal, not clinical evidence. They come from nootropics forums, peptide-user community guides, and biohacker reviews, and they represent a real part of how Selank is experienced and discussed — kept clearly separate from what the cited studies established.

What users commonly describe (anecdotal, not clinical evidence): The most consistent report is calm without sedation — a softening of background anxiety that does not feel like being slowed down or drugged, frequently contrasted with the fog of benzodiazepines or the emotional flatness of SSRIs. People very commonly use it situationally before presentations, exams, interviews, or difficult conversations and describe markedly fewer nerves and a heart rate that stayed low while thinking stayed clear. A "calm but sharp" focus state is a recurring description: anxious mental chatter quiets and concentration becomes easier, which many attribute to the anxiety relief itself rather than a direct stimulant push. Faster intranasal onset (roughly 20–40 minutes) is commonly reported, which is why it is used as an as-needed tool. Gradual mood lift and stress resilience over one to two weeks of regular use is also described. A notable minority find the effect too subtle or notice nothing at all.

On the adverse side: short per-dose duration (a few hours), prompting some to redose; mild tiredness or over-calm in a minority who push the amount used; nasal dryness, burning, sneezing, or tenderness with intranasal use; occasional mild headache; indirectly easier sleep for some (fewer racing anxious thoughts) but mildly activating for others.

Cited safety cautions:

• Unregulated supply. Outside Russia, Selank is sold as a research chemical with supplier-dependent purity and no required sterility testing.
• Limited long-term human safety data. Human clinical experience is restricted to short Russian trials; long-term chronic use in healthy people is not characterized in independent literature.
• Interaction unknowns from multiple pathways. Selank touches GABAergic, opioid, monoaminergic, and immune signaling. A rodent study found the largest anxiety effect when Selank was combined with diazepam ^[9] — suggesting additive GABAergic interaction with real sedative medications. Combination with benzodiazepines, opioids, SSRIs, or immunomodulating drugs has unstudied potential for additive or unexpected effects.
• Immune-signaling dimension. The tuftsin-derived shift in Th1/Th2 balance ^[12] is a real mechanism with unknown long-term consequences, especially in people with autoimmune conditions or on immunomodulating therapy.
• Not a substitute for clinical care. Persistent or impairing anxiety is a medical condition. An unapproved research peptide is not a replacement for clinical evaluation and established treatment.
• Pregnancy, nursing, pre-existing conditions. No safety data exist in these populations; the multi-pathway pharmacology makes the absence of data a reason for caution, not reassurance.

Where it fits in cognitive research

Selank occupies a distinct niche from Semax on this desk. Where Semax is primarily a neuroprotective and neurotrophic compound — its focus effects tied to BDNF upregulation and cerebral ischemia models ^[3][4] — Selank approaches cognition through the anxiety-reduction door: when anxious mental noise quiets, the same cognitive resources feel sharper without any direct stimulant action. Its evidence is more explicitly human-adjacent than Semax's (Russian clinical trials in patients, not just rodent models), yet arguably thinner on the mechanistic side in terms of Western-replicable molecular data. Together they sketch two complementary approaches to cognitive research peptides. See how they compare on the comparison page.